Feedback
Settings

Settings

Goto Application

68,036 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N7/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 6,804
1.WO/2025/130867METHOD FOR INHIBITING TRANSCRIPTIONAL ACTIVITY OF RESIDUAL AAV VECTOR PLASMID AND PLASMID BACKBONE
WO - 26.06.2025
Int.Class C12N 15/861
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
861Adenoviral vectors
 Appl.No PCT/CN2024/139956 Applicant SUZHOU GENASSIST THERAPEUTICS CO., LTD Inventor HE, Chunyan
Provided are a method for inhibiting the transcriptional activity of a residual AAV vector plasmid and a plasmid backbone, and a nucleic acid construct comprising a transcription-inhibitory element, a recombinant AAV vector plasmid comprising the nucleic acid construct, and an AAV product prepared by using the recombinant AAV vector plasmid. By means of inhibiting the transcriptional activity of ITR in the AAV vector plasmid, the transcription-inhibitory element is used for inhibiting transcription products generated by the residual AAV vector plasmid and the reverse packaging of the plasmid backbone.
2.WO/2025/133247METHODS FOR AAV VECTOR RE-ADMINISTRATION
WO - 26.06.2025
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
 Appl.No PCT/EP2024/088101 Applicant GENETHON Inventor BUJ-BELLO, Ana
The invention relates to a combination of a recombinant AAVpo1 vector and a recombinant AAV9, AAVrh10 or AAVrh74 vector for use in the gene therapy of muscle and/or nervous system disorders in an individual in need thereof.
3.WO/2025/129693RECOMBINANT ONCOLYTIC HERPES VIRUS HAVING AN OXYGEN DEPENDENT DEGRADATION DOMAIN
WO - 26.06.2025
Int.Class C12N 7/01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
01Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
 Appl.No PCT/CN2023/141255 Applicant VIROGIN BIOTECH (SHANGHAI) LTD. Inventor ZHANG, Kuan
Provided herein is a recombinant herpes simplex viruses (HSV) having a modified oncolytic herpes virus genome, wherein the modified oncolytic herpes virus genome comprises an O2-dependent degradation domain (ODD) operably linked to a copy of an HSV gene.
4.20250205328CONTROLLED RELEASE VACCINE FORMULATIONS
US - 26.06.2025
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No 18847437 Applicant Merck Sharp & Dohme LLC Inventor Akhilesh Bhambhani

The present disclosure provides, among other things, a vaccine composition that includes HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82, where the vaccine composition provides enhanced or comparable HPV vaccine response in comparison to a similar multiple-dose vaccine.

5.20250205327CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS M-SEGMENT NUCLEIC ACID VACCINE AND METHODS OF USE AND PRODUCTION
US - 26.06.2025
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No 18029576 Applicant THE UNITED STATES GOVERNMENT, AS REPRESENTED BY THE SECRETARY OF THE ARMY Inventor Aura R. GARRISON

Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus that causes severe hemorrhagic fever disease in humans. Currently, no licensed CCHF vaccines exist, and the protective epitopes remain unclear. Here, we tested a DNA vaccine expressing the M-segment glycoprotein precursor gene (GPC) of the laboratory CCHFV strain CCHFV-IbAr 10200 (CCHFV-M10200). Increasing the dose of CCHFV-M 10200 provides complete protection from homologous CCHFV challenge in mice, and significant (80%) protection from challenge with the clinically relevant, heterologous CCHFV-Afg09-2990 strain. We also report complete protection from CCHFV-Afg09-2990 challenge following vaccination with a CCHFV-Afg09-2990 GPC expressing DNA vaccine (CCHFV-M Afgog). Finally, we show that the non-structural M-segment protein, GP38, influences CCHF vaccine immunogenicity and provides significant protection from homologous CCHFV challenge. Our results demonstrate that M-segment DNA vaccines elicit protective CCHF immunity and further illustrate the immunorelevance of GP38.

6.WO/2025/132695RECOMBINANT RHABDOVIRUS ENCODING FOR A GASDERMIN
WO - 26.06.2025
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
 Appl.No PCT/EP2024/087270 Applicant BOEHRINGER INGELHEIM INTERNATIONAL GMBH Inventor NOLDEN, Tobias
The present invention relates to the field of oncolytic viruses and in particular to a recombinant rhabdovirus, such as vesicular stomatitis virus encoding in its genome for a gasdermin. The invention is further directed to the use of the recombinant virus in the treatment of cancer and also to methods for producing such viruses.
7.20250207106COMPOSITION AND METHODS FOR ADENO-ASSOCIATED VIRUS PRODUCING STABLE HUMAN EMBRYONIC KIDNEY-293 CELL LINES
US - 26.06.2025
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
 Appl.No 18990358 Applicant GENENTECH, INC. Inventor Chi Kin Domingos Ng

The presently disclosed subject matter relates to compositions and methods for the generation of stable human embryonic kidney-293 (HEK-293) cell lines for adeno-associated virus (AAV) production.

8.WO/2025/129231A DIRECTED EVOLUTION SYSTEM
WO - 26.06.2025
Int.Class C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
 Appl.No PCT/AU2024/050763 Applicant THE UNIVERSITY OF SYDNEY Inventor HESSELSON, Daniel
The present invention relates to a system for evolving a target biomolecule, methods of using such system and composition comprising said system.
9.20250205329MUTANTS OF RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEINS
US - 26.06.2025
Int.Class A61K 39/155
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
155Paramyxoviridae, e.g. parainfluenza virus
 Appl.No 19017356 Applicant YIKANG BIOTECH (SUZHOU) CO., LTD. Inventor Lei CHEN

The present disclosure relates to the field of biomedicine, and in particular, to an improved mutant of a respiratory syncytial virus (RSV) fusion (F) protein and uses thereof. The mutant can form a trimeric structure without introducing a heterologous trimerization domain. Meanwhile, through mutation designs such as releasing internal electrostatic repulsion, deleting the furin cleavage site, truncating the C-terminal domain, and introducing interchain disulfide bonds, the protein is stabilized in the pre-fusion conformation and exhibits enhanced stability. The mutant in the present disclosure is highly immunogenic when used as a vaccine or a vaccine component and can induce the production of a high level of neutralizing antibodies in the immunized animal, which can be used in the preparation of a vaccine for the prevention or treatment of RSV infection, and can also be used as a reagent for the detection of RSV.

10.WO/2025/133030PRIME-BOOST IMMUNIZATION AGAINST INFLUENZA
WO - 26.06.2025
Int.Class A61K 39/145
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
145Orthomyxoviridae, e.g. influenza virus
 Appl.No PCT/EP2024/087768 Applicant INSTITUT FÜR VIROLOGIE UND IMMUNOLOGIE (IVI) Inventor SUMMERFIELD, Artur
The invention relates to compositions and methods for immunisation against influenza virus.
# -